Crucell Announces STAR Arrangement With Medarex

Dutch biotechnology company Crucell N.V. announced that it has started an evaluation program with Medarex, Inc., based in Princeton, New Jersey, to optimize the application of Crucell's STAR technology in bioreactor culture. The program will be performed with a fully human antibody developed using Medarex's UltiMAb technology. Further details were not disclosed.

()a href="http://www.primezone.com/newsroom/?d=79153" target="_blank">PrimeZone